Список литературы к Главе 13

1. Byrd, J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369, N 1. P. 32–42.

2. Byrd J.C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia // N. Engl. J. Med. 2014. Vol. 371, N 3. P. 213–223.

3. Byrd, J.C. et al. Three­year follow­up of treatment­naive and previously treated patients with CLL and SLL receiving single­agent ibrutinib // Blood. 2015. Vol. 125, N 16. P. 2497–2506.

4. Moreno, C. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first­line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open­label, phase 3 trial // Lancet Oncol. 2019. Vol. 20, N 1. P. 43–56.

5. Burger J.A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia // N. Engl. J. Med. 2015. Vol. 373, N 25. P. 2425–2437.

6. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.

7. Bruton O.C. et al. Absence of serum gamma globulins // AMA Am. J. Dis. Child. 1952. Vol. 84, N 5. P. 632–636.

8. Rawlings D.J. et al. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice // Science. 1993. Vol. 261, N 5119. P. 358–361.

9. Tsukada S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X­linked agammaglobulinemia. 1993 // J. Immunol. 2012. Vol. 188, N 7. P. 2936–2947.

10. Rickert R.C., New insights into pre­BCR and BCR signalling with relevance to B cell malignancies // Nat. Rev. Immunol. 2013. Vol. 13, N 8. P. 578–591.

11. Singh J., Petter R.C., Kluge A.F. Targeted covalent drugs of the kinase family // Curr. Opin. Chem. Biol. 2010. Vol. 14, N 4. P. 475–480.

12. Buggy J.J., Elias L. Bruton tyrosine kinase (BTK) and its role in B­cell malignancy // Int. Rev. Immunol. 2012. Vol. 31, N 2. P. 119–132.

13. Wiestner A., Emerging role of kinase­targeted strategies in chronic lymphocytic leukemia // Blood. 2012. Vol. 120, N 24. P. 4684-4691.

14. Liu X. et al. Intracellular MHC class II molecules promote TLR­triggered innate immune responses by maintaining activation of the kinase Btk // Nat. Immunol. 2011. Vol. 12, N 5. P. 416–424.

15. Treon S.P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia // N. Engl. J. Med. 2012. Vol. 367, N 9. P. 826–833.

16. Shinners N.P. et al. Bruton’s tyrosine kinase mediates NF­kappa B activation and B cell survival by B cell­activating factor receptor of the TNF­R family // J. Immunol. 2007. Vol. 179, N 6. P. 3872–3880.

17. de Gorter D.J. et al. Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine­controlled B cell migration and homing // Immunity. 2007. Vol. 26, N 1. P. 93–104.

18. Packham G. et al. The outcome of B­cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy // Haematologica. 2014. Vol. 99, N 7. P. 1138–1148.

19. Dal Porto J.M. et al. B cell antigen receptor signaling 101 // Mol. Immunol. 2004. Vol. 41, N 6–7. P. 599–613.

20. Deglesne P.A. et al. Survival response to B­cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression // Cancer Res. 2006. Vol. 66, N 14. P. 7158–7166.

21. Bernal A. et al. Survival of leukemic B cells promoted by engagement of the antigen receptor // Blood. 2001. Vol. 98, N 10. P. 3050–3057.

22. Wodarz D. et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib // Blood. 2014. Vol. 123, N 26. P. 4132–4135.

23. Ponader S. et al. The Bruton tyrosine kinase inhibitor PCI­32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo // Blood. 2012. Vol. 119, N 5. P. 1182–1189.

24. Boissard F. et al. Nurse­like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients // Blood Cancer J. 2015. Vol. 5, N 10. P. e355.

25. de Weers M. et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages // Eur. J. Immunol. 1993. Vol. 23, N 12. P. 3109–3114.

26. Honigberg L.A. et al. The Bruton tyrosine kinase inhibitor PCI­32765 blocks B­cell activation and is efficacious in models of autoimmune disease and B­cell malignancy // Proc. Natl Acad. Sci. USA. 2010. Vol. 107, N 29. P. 13 075–13 080.

27. Byrd J.C. et al. Acalabrutinib (ACP­196) in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 323–332.

28. Dubovsky J.A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1­selective pressure in T lymphocytes // Blood. 2013. Vol. 122, N 15. P. 2539–2549.

29. Wang A. et al. Ibrutinib targets mutant­EGFR kinase with a distinct binding conformation // Oncotarget. 2016. Vol. 7, N 43. P. 69 760–69 769.

30. Levade M. et al. Ibrutinib treatment affects collagen and von Willebrand factor­dependent platelet functions // Blood. 2014. Vol. 124, N 26. P. 3991–3995.

31. Lanning B.R. et al. A road map to evaluate the proteome­wide selectivity of covalent kinase inhibitors // Nat. Chem. Biol. 2014. Vol. 10, N 9. P. 760–767.

32. de Jong J. et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia // Cancer Chemother. Pharmacol. 2015. Vol. 75, N 5. P. 907–916.

33. Bernard S. et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse // Blood. 2015. Vol. 126, N 14. P. 1695–1698.

34. Grommes C., Pastore A., Gavrilovic I., Kaley T., Nolan C., Omuro A.M. et al. Single­agent ibrutinib in recurrent/refractory central nervous system lymphoma // Blood. 2016. Vol. 128, N 22. 58th Annual Meeting Abstracts. Abstr. 783.

35. Advani R.H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI­32765) has significant activity in patients with relapsed/refractory B­cell malignancies // J. Clin. Oncol. 2013. Vol. 31, N 1. P. 88–94.

36. Hallek M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute­Working Group 1996 guidelines // Blood. 2008. Vol. 111, N 12. P. 5446–5456.

37. Byrd J.C. et al. Long­term follow­up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab // Blood. 2019. Vol. 133, N 19. P. 2031–2042.

38. Byrd J.C. et al. Long­term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow­up of the RESONATE study // J. Clin. Oncol. 2017. Vol. 35, N 15. Suppl. P. 7510.

39. Munir T. et al. Final analysis from RESONATE: Up to six years of follow­up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma // Am. J. Hematol. 2019. Vol. 94, N 12. P. 1353–1363.

40. Wierda W.G. et al. Ofatumumab is active in patients with fludarabine­refractory CLL irrespective of prior rituximab: results from the phase 2 international study // Blood. 2011. Vol. 118, N 19. P. 5126–5129.

41. Chanan­Khan A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double­blind, phase 3 study // Lancet Oncol. 2016. Vol. 17, N 2. P. 200–211.

42. Fraser G. et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma // Leukemia. 2019. Vol. 33, N 4. P. 969–980.

43. O’Brien S. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE­17): a phase 2, open­label, multicentre study // Lancet Oncol. 2016. Vol. 17, N 10. P. 1409–1418.

44. Ahn I.E. et al. Depth and durability of response to ibrutinib in CLL: 5­year follow­up of a phase 2 study // Blood. 2018. Vol. 131, N 21. P. 2357–2366.

45. O’Brien S. et al. Single­agent ibrutinib in treatment­naïve and relapsed/refractory chronic lymphocytic leukemia: a 5­year experience // Blood. 2018. Vol. 131, N 17. P. 1910–1919.

46. Barr P.M. et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL // Blood. 2017. Vol. 129, N 19. P. 2612–2615.

47. Winqvist M. et al. Real­world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group // Haematologica. 2016. Vol. 101, N 12. P. 1573–1580.

48. Mato A.R. et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience // Blood. 2016. Vol. 128, N 18. P. 2199–2205.

49. Никитин Е.А., Дмитриева Е.А., Пантелеев М.А., Емелина Е.И., Иванова В.Л., Кочкарева Ю.Б. и др. Ибрутиниб в лечении рефрактерного хронического лимфолейкоза // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2017. Т. 10, № 3. С. 271–281.

50. O’Brien S. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open­label, multicentre, phase 1b/2 trial // Lancet Oncol. 2014. Vol. 15, N 1. P. 48–58.

51. Byrd J.C. et al. Ibrutinib Treatment for first­line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC­1102 study // Clin. Cancer Res. 2020. Vol. 26, N 15. P. 3918–3927.

52. Burger J.A. et al. Long­term efficacy and safety of first­line ibrutinib treatment for patients with CLL/ SLL: 5 years of follow­up from the phase 3 RESONATE­2 study // Leukemia. 2020. Vol. 34, N 3. P. 787–798.

53. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions // N. Engl. J. Med. 2014. Vol. 370, N 12. P. 1101–1110.

54. Woyach J.A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL // N. Engl. J. Med. 2018. Vol. 379, N 26. P. 2517–2528.

55. Davids M.S. et al. Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients. Washington, DC : American Society of Hematology, 2016.

56. Davids M.S. et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single­arm, multicentre, phase 2 trial // Lancet Haematol. 2019. Vol. 6, N 8. P. e419–e428.

57. Jain N. et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for first­line treatment of IGHV­mutated CLL and without del(17p)/mutated TP53 // Blood. 2019. Vol. 134. P. 357–357.

58. Thompson P.A. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.

59. Burger J.A. et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia // Blood. 2019. Vol. 133, N 10. P. 1011–1019.

60. Weiner G.J. Rituximab: mechanism of action // Semin. Hematol. 2010. Vol. 47, N 2. P. 115–123.